Hepatic manifestations of gastrointestinal diseases inflammatory bowel disease, Celiac disease, and Whipple's disease

Clinics in Liver Disease

Volumn 6, Issue 4, 2002, Pages 1013-1032

  Smyth, Claire ^a   Kelleher, Dermot ^a   Keeling, Paul W N ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; BILIRUBIN; CA 19-9 ANTIGEN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; CEFTRIAXONE; COLESTYRAMINE; CORTICOSTEROID; COTRIMOXAZOLE; HLA B8 ANTIGEN; HLA DQ ANTIGEN; HLA DR1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METALLOPROTEINASE; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OPIATE ANTAGONIST; PROTEIN P53; PYRUVATE DEHYDROGENASE COMPLEX; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

AUTOIMMUNE HEPATITIS; CANCER RISK; CELIAC DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; GASTROINTESTINAL DISEASE; HUMAN; IMAGE ANALYSIS; IMMUNOGENETICS; INTESTINE LIPODYSTROPHY; LIVER TRANSPLANTATION; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANIMALS; CELIAC DISEASE; CHOLANGITIS, SCLEROSING; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LIVER TRANSPLANTATION; WHIPPLE DISEASE;

EID: 0036866234     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00055-7     Document Type: Review

References (84)

1. Chapman RW, Agnus PW. The effect of gastrointestinal diseases on the liver and biliary tract. In: Bircher J, Benhumau J, McIntyre N, editors. Oxford Textbook of Clinical Hepatology. 2nd Edition. New York: Oxford University Press; 1999 p. 1685-91.
2. Angulo P, DeSotel CK, Gershwin ME, et al. The profile and significance of serum auto antibodies in primary sclerosing cholangitis [abstract]. Hepatology 1998;28:444A.
3. Chapman RW, Arbough BA, Rhodes JM, et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870-7.
4. Boberg KM, Schrumpf E, Fausa O, et al. Hepatobiliary disease in ulcerative colitis: An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand J Gastroenterol 1994;29:144-752.
5. Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:629-42.
6. Farrant JM, Doherty DG, Donaldson PT, et al. Amino-acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992;16:390-5.
7. Mehal WZ, Lo Y-MD, Wordsworth BP, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994;106:160-7.
8. Olerup O, Olsson R, Hultcrantz R, et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-8.
9. Aguilar HI, Nuako K, Krom RAF, et al. Do primary sclerosing cholangitis (PSC) patients who express HLA-DR4 haplotype have a more rapidly progressive disease [abstract]? Hepatology 1994;20:154A.
10. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001;36:886-90.
11. Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
12. Thomson RK, Arthur MJ. Mechanisms of liver cell damage and repair. Eur J Gastro Hepatol 1999;11:949-95.
13. Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the Stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001;121:124-30.
14. Bo X, Broome U, Remberger M, et al. Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001;49:131-41.
15. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor α-308 but not the interleukin 10-627 promoter polymorhpism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-94.
16. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis. J Hepatol 2000;33:520-7.
17. Fulcher AS, Turner MA, Franklin KJ, et al. Primary sclerosing cholangitis: Evaluation with MR cholangiography - A case-control study. Radiology 2000;215:71-80.
18. Larusso NF, Wiesner RH, Ludwig J. Sclerosing cholangitis. In: Bircher J, Benhumau J, McIntyre N, editors. Oxford Textbook of Clinical Hepatology. 2nd Edition. New York: Oxford University Press; 1999 p. 1121-30.
19. Komatsu K, Shimosegawa T, Kikuchi S, et al. Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis. Intern Med 2000;39:1049-53.
20. Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
21. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
22. Van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisolone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000;95:2015-22.
23. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-7.
24. Parkes M, Booth JC, Pillai G, et al. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol 2001;33:319-22.
25. Balayut AR, Sherman S, Lehman GA, et al. Impact of endosopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointes Endosc 2001;53:308-12.
26. Kaya M, Peterson BT, Angulo P, et al. Balloon dilitation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1059-66.
27. Springer DJ, Gaing AA, Siegel JH. Radiologic regression of primary sclerosing cholangitis following combination therapy with an endoprosthesis and ursodeoxycholic acid. Am J Gastroenterol 1993;88:1957-9.
28. Lombard M, Farrant M, Karani J, et al. Improving biliary-enteric drainage in primary sclerosing cholangitis: Experience with endoscopic methods. Gut 1991;32:1364-8.
29. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999;31:305-9.
30. Ferrari Junior AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994;40:140-5.
31. Foutch PG, Kerr DM, Harlan JR, et al. Endoscopic retrograde wire-guided brush cytology for diagnosis of patients with malignant obstruction of the bile duct. Am J Gastroenterol 1990;85:791-5.
32. Scudera PL, Koizumi J, Jacobson IM. Brush cytology evaluation of lesions encountered during ERCP. Gastrointest Endosc 1990;36:281-4.
33. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-9.
34. Ahrendt SA, Rashid A, Chow JT, et al. p53 over expression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000;7:426-31.
35. Kubicha S, Kuhnel F, Flemming P, et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001;48:403-8.
36. Broome U, Lofberg R, Veress R, et al. Primary sclerosing cholangitis and ulcerative colitis: Indicatory of increased neoplastic potential. Hepatology 1995;22:1404-8.
37. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9.
38. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-9.
39. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
40. Devlin J, O'Grady J. Indications for referral and assessment in adult liver transplantation: A clinical guideline. Gut 1999;45:V11-V122.
41. Sladeen K, Friman S, Olausson M, et al. Follow-up after liver transplantation for primary sclerosing cholangitis: Effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999;34:535-40.
42. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
43. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999;29:1050-6.
44. Hagimoto T, Seo M, Okada M, et al. Portal vein thrombosis successfully treated with a colectomy in active ulcerative colitis: A report of a case. Dis Colon Rectum 2001;44:587-90.
45. Miyazaki Y, Shinomura Y, Kitamura S, et al. Portal vein thrombosis associated with active ulcerative colitis: Percutaneous transhepatic recanalization. Am J Gastroenterol 1995;90:1533-4.
46. Praderio L, Dagna L, Longhi P, et al. Budd-Chiari syndrome in a patient with ulcerative colitis: Association with anticardiolipin antibodies. J Clin Gastroenterol 2000;30:203-4.
47. Whiteford MH, Moritz MJ, Ferber A, et al. Budd-Chiari syndrome complication restorative proctocolectomy for ulcerative colitis: Report of a case. Dis Colon Rectun 1999;42:1220-4.
48. Kraut J, Berman JH, Gunasekaran TS, et al. Hepatic vein thrombosis (Budd-Chiari syndrome) in an adolescent with ulcerative colitis. J Pediatr Gastroenterol Nutr 1997;25:417-20.
49. Mahmud N, Molloy A, McPartlin J, et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999;45:389-94.
50. Feighery C. Coeliac disease. BMJ 1999;319:236-8.
51. Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000;119:234-42.
52. Logan RF, Ferguson A, Weir DG, et al. Primary biliary cirrhosis and celiac disease: An association? Lancet 1978;1:230-3.
53. Shanahan F, O'Regan PF, Crowe JP. Primary biliary cirrhosis associated with coeliac disease. Irish Med J 1983;76:282-3.
54. Behr W, Barnert J. Adult celiac disease and primary biliary cirrhosis. Am J Gastroenterol 1986;81:796-9.
55. Bardella MT, Quatrini M, Zuin M, et al. Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J Gastroenterol 1997;92:1524-6.
56. Kingham JGC, Parker DR. The association between primary biliary cirrhosis and celiac disease: A study of relative prevalences Gut 1998;42:120-2.
57. Sorensen HT, Thulstrup AM, Blomqvist P, et al. Risk of primary biliary cirrhosis in patients with celiac disease: Danish and Swedish cohort data. Gut 1999;44:736-8.
58. Sherlock S, Heathcote J. Primary biliary cirrhosis. In: Bircher J, Benhumau J, McIntyre N, editors. Oxford Textbook of Clinical Hepatology. 2nd Edition. New York: Oxford University Press; 1999 p 1089-98.
59. Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9.
60. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134-46.
61. Jones EA, ten Kate FJ, ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1165-9.
62. Miyaguchi S, Ebinuma H, lmaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000:47:1518-21.
63. Almasio PL, Floreani A, Chiaramonte M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicines in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 2000;14:1645-52.
64. Sorda J, Findor J. Methotrexate therapy in primary biliary cirrhosis. Acta Gastroenterol Latinoam 2000;30:221-5.
65. Gilroy RK, Lynch SV, Strong RW, et al. Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis. Liver Transpl 2000;6:749-52.
66. Neuberger J. Recurrent primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:669-80.
67. Haagsma EB. Clinical relevance of recurrence of a primary biliary cirrhosis after liver transplantation. Eur J Gastroenterol Hepatol 1999,11:639-42.
68. Neuberger J. PBC and the gut: The villi atrophy, the plot thickens. Gut 1999;44:594-5.
69. Gregory WL, Mehal W, Dunn AN, et al. Primary biliary cirrhosis: Contribution of HLA class II allele DR8. Q J Med 1993;86:393-9.
70. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-73.
71. Morling N, Dalhoff K, Fugger L, et al. DAN polymorphism of HLA class II genes in primary biliary cirrhosis. Immunogenetics 1992;35:112-6.
72. Jones DE. T-cell autoimmunity in primary biliary cirrhosis. Clin Sci (Lond) 1996;91:551-8.
73. Shigematsu H, Shimoda S, Nakamura M, et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: Implications for molecular mimicry and cross-recognition mitochondrial autoantigens. Hepatology 2000;32(5):901-9.
74. Parikh-Patel A, Gold EB, Worman H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 2001;33:16-21.
75. O'Donohue J, Fidler H, Garcia-barcelo M, et al. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatology 1998;28:433-8.
76. Sjoberg K, Lindgren S, Eriksson S. Frequent occurrence of non-specific gliadin antibodies in chronic liver disease: Endomysial but not gliadin antibodies predict celiac disease in patients with chronic liver disease. Scand J Gastroenterol 1997;32:1162-7.
77. Volta U, De Franceschi L, Molinaro N, et al. Frequency and significance of anti-gliadin and antiendomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43:2190-5.
78. Hay JE, Wiesner RH, Shorter RG, et al. Primary sclerosing cholangitis and celiac disease: A novel association. Ann Intern Med 1988;109:713-7.
79. Jacobsen MB, Fausa O, Elgjo K, et al. Hepatic lesions in adult celiac disease. Scand J Gastroenterol 1990;25(7):656-62.
80. Venturini I, Cosenza R, Miglioli L, et al. Adult celiac disease and primary sclerosing cholangitis: Two case reports. Hepatogastroenterology 1998;45:2344-7.
81. Donaldson PT, Norris S. Immunogenetics in PSC. Best Pract Res Clin Gastroenterol 2001;15:611-27.
82. Saint-Marc Girardin MF, Zafrani ES, Chaumette MT, et al. Hepatic granulomas in Whipple's disease. Gatroenterology 1984;86:753-6.
83. Minkari T, Pars B, Erbengi T, et al. A case of Whipple's disease complicated by fatal hepatitis. Hepatogastroenterology 1980;27:322-6.
84. Misra PS, Lebwohl P, Laufer H. Hepatic and appendiceal Whipple's disease with negative jejunal biopsies. Am J Gastroenterol 1981;75:302-6.